SEC EDGAR · Insider purchase
LRMR: Clayton Russell reported buying shares
1 reported purchase of non-derivative securities. Code P includes open-market and private purchases; it does not establish motive.
Follow LRMR- Became public
- Nov 18, 2026, 4:30 PM EST
- Event / period date
- Nov 16, 2026
- Collected
- Nov 18, 2026, 4:47 PM EST
Why this is connected
This filing identifies Larimar Therapeutics, Inc. as the issuer of the security. The company's SEC identifier connects it to LRMR.
Reported transactions
Clayton Russell (Chief Medical Officer)
3,322 shares · Common Stock
Nov 16, 2026 · $3.01 per share
Value calculated from the reported shares and prices: $9,999.22.
Code P covers open-market and private purchases. Grants, option exercises, and tax withholding are excluded from purchase results. Read the source footnotes for ownership and pricing details.
Source evidence
Read the source excerpt or record
<?xml version="1.0"?>
<ownershipDocument>
<schemaVersion>X0609</schemaVersion>
<documentType>4</documentType>
<periodOfReport>2026-11-16</periodOfReport>
<issuer>
<issuerCik>0001374690</issuerCik>
<issuerName>Larimar Therapeutics, Inc.</issuerName>
<issuerTradingSymbol>LRMR</issuerTradingSymbol>
<issuerForeignTradingSymbol></issuerForeignTradingSymbol>
</issuer>
<reportingOwner>
<reportingOwnerId>
<rptOwnerCik>0001530072</rptOwnerCik>
<rptOwnerName>Clayton Russell</rptOwnerName>
</reportingOwnerId>
<reportingOwnerAddress>
<rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
<rptOwnerStreet1>C/O LARIMAR THERAPEUTICS, INC.</rptOwnerStreet1>
<rptOwnerStreet2>THREE BALA PLAZA EAST, SUITE 506</rptOwnerStreet2>
<rptOwnerCity>BALA CYNWYD</rptOwnerCity>
<rptOwnerState>PA</rptOwnerState>
<rptOwnerZipCode>19004</rptOwnerZipCode>
<rptOwnerStateDescription></rptOwnerStateDescription>
</reportingOwnerAddress>
<reportingOwnerRelationship>
<isDirector>false</isDirector>
<isOfficer>true</isOfficer>
<isTenPercentOwner>false</isTenPercentOwner>
<isOther>false</isOther>
<officerTitle>Chief Medical Officer</officerTitle>
</reportingOwnerRelationship>
</reportingOwner>
<aff10b5One>false</aff10b5One>
<nonDerivativeTable>
<nonDerivativeTransaction>
<securityTitle>
<value>Common Stock</value>
</securityTitle>
<transactionDate>
<value>2026-11-16</value>
</transactionDate>
<transactionCoding>
<transactionFormType>4</transactionFormType>
<transactionCode>P</transactionCode>
<equitySwapInvolved>false</equitySwapInvolved>
</transactionCoding>
<transactionAmounts>
<transactionShares>
<value>3322</value>
</transactionShares>
<transactionPricePerShare>
<value>3.01</value>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value>A</value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value>74765</value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value>D</value>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
</nonDerivativeTable>
<ownerSignature>
<signatureName>/s/ Jennifer Johansson, Attorney-in-fact</signatureName>
<signatureDate>2026-11-18</signatureDate>
</ownerSignature>
</ownershipDocument>Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.